Micrus' slashed earnings forecast stirs discontent among shareholders:
This article was originally published in Clinica
Executive Summary
Disgruntled investors in embolic coil device manufacturer Micrus are suing the company for securities fraud - a reaction to the profit warning issued by the company last month. The San Jose, California firm had cut its revenue guidance for fiscal 2008 as a result of uncertainty over the approvals of products by Chinese and Japanese authorities, as well as slower-than expected sales in North America (see Clinica No 1274, p 3). Schatz Nobel Izard (Hartford, Connecticut) and Couglin Stoia Geller Rudman & Robbins (New York) have filed class action lawsuits in a US district court in Florida on behalf of investors who purchased shares in Micrus between February 12 and September 17 2007.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.